UPS Healthcare Expands Global Cold Chain Logistics Network
Marken, the clinical trial logistics operation with UPS Healthcare, has expanded its global network to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials. Plans for the remainder of 2021 and 2022 will support accelerated demand for mRNA therapies, cell and gene therapies, early access and managed access programs. Expansion plans include new locations, expanded cold chain services and packaging solutions.
Marken's ongoing and planned investments include:
- The addition of over 100,000 square feet of GMP-compliant depot operations in Louisville, KY, Great Valley, PA, and Seoul, South Korea.
- A new GMP depot facility in Kiev, Ukraine
- A new GDP depot facility in Osaka, Japan
- New locations in Nairobi, Kenya and Accra, Ghana
- Expansion of its kit assembly facility in Shanghai, China
- New liquid nitrogen (LN2) filling stations within each of its global cell and gene centers of excellence
- Infrastructure expansion at its facilities in Belgium, France, South Africa, India, Taiwan, China, and Singapore
- Packaging and technology enhancements for real-time location tracking and temperature monitoring of cell and gene therapy shipments
This new control center, combined with the existing control center in Durham, NC, US, will support 24/7/365 global monitoring of all complex shipments, including cell and gene shipments.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025